Sprycel (Dasatinib)

Generic Name

Dasatinib

Brand Names

Sprycel, Phyrago

FDA approval date: June 27, 2006

Classification: Kinase Inhibitor

Form: Tablet

What is Sprycel (Dasatinib)?

Dasatinib tablets are indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase. chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy. Dasatinib tablets are indicated for the treatment of pediatric patients 1 year of age and older with Ph+ CML in chronic phase. Newly diagnosed Ph+ ALL in combination with chemotherapy. Dasatinib tablets are kinase inhibitor indicated for the treatment of newly diagnosed adults with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase. adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. adults with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy. pediatric patients 1 year of age and older with Ph+ CML in chronic phase. pediatric patients 1 year of age and older with newly diagnosed Ph+ ALL in combination with chemotherapy.

Approved To Treat

Top Global Experts

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Related Clinical Trials

Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial

Enrollment Status: Recruiting

Publish Date: April 16, 2026

Intervention Type: Other

Summary: In this study researchers propose to do a chart review of all patients that are treated outside of a clinical trial with imatinib, dasatinib, nilotinib, or any other tyrosine kinase inhibitor that becomes FDA approved for the managements of CML that come to MDACC for a second opinion. This is an important population of patients that differs in their management from patients treated in clinical tri...

An International Phase 2 Study of Chemotherapy and Tyrosine Kinase Inhibitors With Blinatumomab in Patients With Newly-Diagnosed Philadelphia Chromosome-Positive or ABL-Class Philadelphia Chromosome-Like B-Cell Acute Lymphoblastic Leukemia

Enrollment Status: Recruiting

Publish Date: April 14, 2026

Intervention Type: Drug, Procedure, Biological, Radiation

Study Phase: Phase 2

Summary: This pilot trial assesses the effect of the combination of blinatumomab with dasatinib or imatinib and standard chemotherapy for treating patients with Philadelphia chromosome positive (Ph+) or ABL-class Philadelphia chromosome-like (Ph-like) B-Cell acute lymphoblastic leukemia (B-ALL). Blinatumomab is a bispecific antibody that binds to two different proteins-one on the surface of cancer cells an...

Combination of Autophagy Selective Therapeutics (COAST) in Advanced Solid Tumors or Relapsed Prostate Cancer, A Phase I/II Trial

Who is this study for: Patients with Solid Tumors

Enrollment Status: Recruiting

Publish Date: March 30, 2026

Intervention Type: Combination product

Study Drugs: Hydroxychloroquine+Metformin+Sirolimus, Hydroxychloroquine+Metformin+Sirolimus+Dasatanib, Hydroxychloroquine+Metformin+Sirolimus+Nelfinavir, Hydroxychloroquine+Metformin+Sirolimus+Nelfinavir+Dasatinib

Study Phase: Phase 1/Phase 2

Summary: The purpose of this Phase I/II study is to determine the safety and effectiveness of up to 5 study drugs used together for the treatment of solid tumor cancers. The drugs are hydroxychloroquine, metformin, sirolimus, dasatinib and nelfinavir and are given orally.

View All Clinical Trials